Synlogic Has Selected Science 37 To Provide Virtual Clinical Trial Technology And Services For Synpheny-3, Its Ongoing Pivotal, Phase 3 Trial Of Investigational Drug Labafenogene Marselecobac (Previously Known As SYNB1934) For Phenylketonuria
Portfolio Pulse from Benzinga Newsdesk
Synlogic has chosen Science 37 to provide virtual clinical trial technology and services for its ongoing pivotal, Phase 3 trial of investigational drug labafenogene marselecobac for Phenylketonuria. The trial aims to study the effectiveness of the drug in PKU patients, with around 150 patients expected to be enrolled and monitored for up to three years. Science 37's platform will ensure data quality and consistency across all research sites.
July 11, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Science 37's partnership with Synlogic for the Phase 3 trial could potentially enhance its reputation in the field of virtual clinical trial technology, which may positively impact the company's stock in the short term.
The partnership with Synlogic could enhance Science 37's reputation in the field of virtual clinical trial technology. This could potentially boost investor confidence in Science 37, positively impacting its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Synlogic's partnership with Science 37 for its Phase 3 trial could potentially enhance the quality and consistency of the trial data, which may positively impact the company's stock in the short term.
The partnership with Science 37 could enhance the quality and consistency of the trial data, which is crucial for the success of the trial and subsequent approval of the drug. This could potentially boost investor confidence in Synlogic, positively impacting its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100